

58



Europäisches Patentamt
European Patent Office
Office européen des brevets



Publication number: **0 415 731 A2**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 90309430.8

(22) Date of filing: 29.08.90

(51) Int. Cl.⁵: **C12N 15/85, C12N 15/52,
C12N 15/86, C12N 7/01,
A61K 48/00, A61K 31/70**

(30) Priority: 30.08.89 GB 8919607

(43) Date of publication of application:
06.03.91 Bulletin 91/10

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(71) Applicant: **THE WELLCOME FOUNDATION
LIMITED**
Unicorn House 160 Euston Road
London NW1 2BP(GB)

(72) Inventor: Huber, Brian
53 Westridge Road
Durham, North Carolina 27713(US)
Inventor: Richards, Cynthia Ann
5616 Welkin Court
Durham, North Carolina 27713(US)
Inventor: Krenitsky, Thomas Anthony
106 Laurel Hill Road
Chapel Hill, North Carolina 27514(US)

(74) Representative: Stott, Michael John et al
The Wellcome Research Laboratories Group
Patents & Agreements Langley Court
Beckenham Kent BR3 3BS(GB)

(54) Novel entities for cancer therapy.

(57) Novel molecular chimaeras produced by recombinant DNA techniques are described. They comprise a target tissue specific transcriptional regulatory sequence (TRS) linked and controlling the expression of a heterologous enzyme for example Varicella Zoster Virus Thymidine Kinase (VZV TK) gene. A molecular chimaera is packaged into a synthetic retroviral particle which is capable of infecting mammalian tissue. This in turn may be administered to a patient, and the TRS will be selectively transcriptionally activated in the target tissue (for example cancerous tissue). Administration of compounds which are selectively metabolised by the enzyme produce cytotoxic or cytostatic metabolites in situ thereby selectively killing or arresting the growth of the target cell.

EP 0 415 731 A2

NOVEL ENTITIES FOR CANCER THERAPY

The present invention relates to molecular chimaeras, infective virions, to methods of their construction, to pharmaceutical formulations containing them, to their use in therapy, particularly virus-directed enzyme prodrug therapy, particularly in the treatment of cancers, more particularly in the treatment of hepatocellular carcinoma, and to the use of agents which can be catalysed by a heterologous enzyme to cytotoxic or cytostatic metabolites, such as purine arabinosides and substituted pyrimidines in virus-directed enzyme prodrug therapy.

Cancer of all forms is one of the major causes of morbidity throughout the world. Research in the area of cancer chemotherapy has produced a variety of antitumour agents which have differing degrees of efficacy. Standard clinically used agents include adriamycin, actinomycin D, methotrexate, 5-fluorouracil, cis platinum, vincristine and vinblastine. However, these presently available antitumour agents are known to have various disadvantages such as toxicity to healthy cells and resistance of certain tumour types. Other forms of therapy such as surgery, are known. However it is appreciated by those skilled in the art that novel approaches and entities for cancer therapies are required.

Hepatocellular carcinoma (HCC) is one of the major malignant diseases in the world today; the greatest incidence being in Japan, China, other parts of the Asia and sub-Saharan Africa. Recent evidence suggests that the incidence of hepatocellular carcinoma in Europe and North America is increasing. The disease is estimated to be responsible for or involved in up to approximately 1,250,000 deaths a year and as such is numerically, one of the world's major malignant diseases.

The prognosis of HCC is always poor with the world-wide frequency rate almost equalling the mortality rate. After diagnosis, the median survival time is less than four months. Long-term survival, defined as survival longer than one year after diagnosis, is seen only occasionally. Most HCC patients succumb to either the complications of liver failure with or without massive bleeding, or to the general effects of a large tumour burden, with cachexia, malnutrition, infection and sepsis. Though distant metastases occur (up to 90% of patients have metastatic tumour at time of death), regional disease most often limits survival. Consequently, therapies directed towards control of hepatic tumour are appropriate although it will be appreciated that treatment of the metastatic disease is also of great importance. (Kew M.C. Postgraduate Medical Journal 59 (Suppl.) 78-87 (1983) and Berk.P. (Ed) Seminars in Liver Disease 4, No. 2, Thieme-Stratton Inc. N.Y. N.Y. (1984)).

Current therapies available to the clinician are on the whole ineffective as a cure for this disease (Nerenstone et al, Cancer Treatment Reviews 15, 1-31 (1988)). To date, surgery continues to be the only potential cure. However, at the time of diagnosis, the overwhelming majority of patients are not able to undergo radical surgery. In certain studies (Nerenstone et al supra) it was found that less than 3% of patients were considered capable of undergoing surgery and of the small percentage that so do approximately 50% suffer from postoperative morbidity (Nerenstone et al supra).

Systemic single and combination agent chemotherapy and radiation are relatively ineffective and this emphasises the need for new approaches and therapies for the treatment of this disease.

Gene therapy involves the stable integration of new genes into particular target cells and the expression of those genes, once they are in place, to alter the phenotype of that particular target cell (for review see Anderson, W.F. Science 226: 401-409, 1984; McCormick, D. Biotechnology 3 : 690-693, 1985). Gene therapy may be beneficial for the treatment of genetic disease which involve the replacement of one defective or missing enzyme, such as hypoxanthine-guanine phosphoribosyl transferase in Lesch Nyhan disease; purine nucleoside phosphorylase in severe immunodeficiency disease and adenosine deaminase in severe combined immunodeficiency disease. As yet, gene therapy has not been used in the clinic, although in certain disorders, certain types of gene therapy are likely to be used imminently.

It has been found by the present inventors that it is possible to selectively arrest the growth of or kill mammalian carcinoma cells with chemical agents capable of selective conversion to cytotoxic or cytostatic metabolites. This is achieved by the construction of a molecular chimaera comprising a "target tissue-specific" transcriptional regulatory sequence (TRS) which is selectively activated in target tissues, such as cancerous cells: this controls the expression of a heterologous enzyme. This molecular chimaera may be manipulated via suitable vectors and incorporated into an infective virion. Upon administration of an infective virion containing the molecular chimaera to a patient, the enzyme is selectively expressed in the target cell. Administration of compounds which are selectively metabolised by the enzyme into metabolites which are either further metabolised to, or are in fact cytotoxic or cytostatic agents can then be achieved in situ.

The invention is generally applicable and is demonstrated with respect to hepatocellular carcinoma.

As mentioned above the overwhelming percentage of patients suffering from hepatocellular carcinoma

die from the primary tumour. However, approximately 90% of HCC patients have overt metastatic disease at time of death. These metastases exhibit the typical phenotype of the primary tumour and as such these metastases will also selectively express the heterologous enzyme and thus selectively activate administered compounds as herein defined to cytotoxic or cytostatic metabolites.

5 A number of enzyme pro-drug combinations may be used; providing the enzyme is capable of selectively activating the administered compound either directly or through an intermediate to a cytostatic or cytotoxic metabolite. Equally the choice of compound will depend on the enzyme system used, but must be selectively metabolised by the enzyme either directly or indirectly to a cytotoxic or cytostatic metabolite. The term heterologous enzyme as used herein, refers to an enzyme which displays the appropriate
10 characteristics of selectivity.

The varicella zoster virus (VZV) encodes a specific thymidine kinase protein. The gene has been cloned, sequenced and characterised (J. Gen. Virol. 67 : 1759-1816 (1986)). The VZV thymidine kinase will, in contrast to the mammalian enzyme, selectively monophosphorylate specific purine arabinosides and substituted pyrimidine compounds. Moreover, the present inventors have found that certain purine and
15 pyrimidine analogues particularly those of formulae (I) and (II) as hereinafter defined are converted to cytotoxic or cytostatic metabolites in specific mammalian cells which are genetically modified to selectively express VZV thymidine kinase. For example 9-(β -D-arabinofuranosyl)-6-methoxy-9 H-purine is converted to 9- β -D-arabinofuranosyl adenine triphosphate [Ara ATP].

Other enzyme pro-drug combinations include the bacterial (for example from *Pseudomonas*) enzyme
20 carboxypeptidase G2 with the prodrug para-N-bis (2-chloroethyl) aminobenzoyl glutamic acid. Cleavage of the glutamic acid moiety from this compound releases a toxic benzoic acid mustard; alkaline phosphatase from, for example, calf intestine, will convert inactive phosphorylated compounds such as etoposide-phosphate, doxorubicin-phosphate, mitomycin phosphate, to toxic dephosphorylated metabolites. Penicillin-V amidase will convert phenoxyacetamide derivatives of doxorubicin and melphalan to toxic metabolites and
25 the fungal (for example from *Fusarium oxysporum*) cytosine deaminase will convert 5-fluorocytosine to toxic 5-fluorouracil.

In mammalian cells, certain genes are ubiquitously expressed. Most genes, however, are expressed in a temporal and/or tissue-specific manner, or are activated in response to extracellular inducers, for example certain genes are actively transcribed only at very precise times in ontogeny in specific cell types or in
30 response to some inducing stimulus. This regulation is mediated in part by the interaction between transcriptional regulatory sequences (which are for example promoter and enhancer regulatory DNA sequences), and sequence-specific, DNA-binding transcriptional protein factors.

The present inventors have found that it is possible to alter certain mammalian tissues, eg. liver tissue or transformed liver tissue, to selectively express a heterologous enzyme as herein before defined, eg. VZV
35 thymidine kinase. This is achieved by the construction of molecular chimaeras in an expression cassette.

Expression cassettes themselves are well known in the art of molecular biology. Such an expression cassette will contain all essential DNA sequences required for expression of the heterologous enzyme in a mammalian cell. For example, a preferred expression cassette will contain a molecular chimaera containing the coding sequence for VN TK, an appropriate polyadenylation signal for a mammalian gene (ie. a
40 polyadenylation signal which will function in a mammalian cell), and suitable enhancers and promoter sequences in the correct orientation.

In mammalian cells, normally two DNA sequences are required for the complete and efficient transcriptional regulation of genes that encode messenger RNAs in mammalian cells: promoters and enhancers. Promoters are located immediately upstream (5') from the start site of transcription. Promoter
45 sequences are required for accurate and efficient initiation of transcription. Different gene-specific promoters reveal a common pattern of organisation. A typical promoter includes an AT-rich region called a TATA box (which is located approximately 30 base pairs 5' to the transcription initiation start site) and one or more upstream promoter elements (UPE). The UPEs are a principle target for the interaction with sequence-specific nuclear transcriptional factors. The activity of promoter sequences are modulated by other
50 sequences called enhancers. The enhancer sequence may be a great distance from the promoter in either an upstream (5') or downstream (3') position. Hence, enhancers operate in an orientation- and position-independent manner. However, based on similar structural organisation and function that may be interchanged the absolute distinction between promoters and enhancers is somewhat arbitrary. Enhancers increase the rate of transcription from the promoter sequence. It is predominantly the interaction between sequence-specific transcriptional factors with the UPE and enhancer sequences that enable mammalian cells to
55 achieve tissue-specific gene expression. The presence of these transcriptional protein factors (tissue-specific, trans-activating factors) bound to the UPE and enhancers (cis-acting, regulatory sequences) enable other components of the transcriptional machinery, including RNA polymerase, to initiate transcription with

tissue-specific selectivity and accuracy.

The selection of the transcriptional regulatory sequence, in particular the promoter and enhancer sequence will depend on the targeted tissue. Examples include, the albumin (ALB) and alpha-fetoprotein (AFP) transcriptional regulatory sequence (for example, the promoter and enhancer) specific for normal hepatocytes and transformed hepatocytes respectively; the transcriptional regulatory sequence for carcino-embryonic antigen (CEA) for use in transformed cells of the gastrointestinal tract, lung, breast and other tissues; the transcriptional regulatory sequence for tyrosine hydroxylase, choline acetyl transferase or neuron specific enolase for use in neuroblastomas; the transcriptional regulatory sequence for glial fibrillary acidic protein for use in gliomas; the transcriptional regulatory sequence for insulin for use in tumours of the pancreas.

Further examples include the transcriptional regulatory sequence specific for gamma-glutamyltranspeptidase for use in certain liver tumours and dopa decarboxylase for use in certain tumours of the lung.

In addition the transcriptional regulatory sequences from certain oncogenes may be used as these are expressed predominantly in certain tumour types. Good examples of these include the HER-2/neu oncogene regulatory sequence which is expressed in breast tumours and the regulatory sequence specific for the N-myc oncogene for neuroblastomas.

The ALB and AFP genes exhibit extensive homology with regard to nucleic acid sequence, gene structure, amino acid sequence and protein secondary folding (for review see Ingram et al PNAS 78 4694-4698 (1981)). These genes are independently but reciprocally expressed in ontogeny. In normal development ALB transcription is initiated shortly before birth and continues throughout adulthood. Transcriptional expression of ALB in the adult is confined to the liver. AFP is normally expressed in fetal liver, the visceral endoderm of the yolk sac and the fetal gastrointestinal tract, but declines to undetectable levels shortly after birth and is not significantly expressed in nonpathogenic or non-regenerating adult liver or in other normal adult tissues. However, AFP transcription in adult liver often increases dramatically in HCC. In addition, transcription may also be elevated in non-seminomatous and fixed carcinoma of the testis; in endodermal sinus tumours, in certain teratocarcinomas, and in certain gastrointestinal tumours. Liver-specific expression of AFP and ALB is the result of interactions of the regulatory sequences of their genes with trans-activating transcriptional factors found in nuclear extracts from liver. The ALB and AFP transcriptional regulatory sequences are preferred for generating hepatoma-specific or general liver-specific, expression respectively, of molecularly combined genes since the AFP and ALB genes are regulated at the transcriptional level and their mRNAs are among the most abundant polymerase II transcripts in the liver.

Several mammalian ALB and AFP promoter and enhancer sequences have been identified (for review see Genes and Develop. 1 : 268-276 (1987); Science 235 : 53-58 (1987); The Journal of Biol.Chemistry 262 : 4812-4818 (1987)). These sequences enable the selective and specific expression of genes in liver hepatocytes (normal and transformed) and hepatomas, respectively.

For example as shown in figure 1 a mammalian ALB promoter is contained within 300 bp fragment 5' to the transcription initiation start site of the albumin gene. The sequence contained between 300 bp 5' and 8,500 bp 5' to the transcription initiation start site of the murine albumin gene is dispensable for liver-specific expression. However, a liver-specific enhancer sequence is contained in a fragment located from 8,500 bp 5' to 10,400 bp 5' to the transcription initiation start site (Fig 1A). If the ALB promoter and enhancer elements are present, liver-specific expression of a heterologous structural gene positioned in a proper 3' orientation can be achieved (Fig 1B). Liver-specific expression of a 3' heterologous structural gene positioned in the proper orientation to the ALB promoter and enhancer sequences is also maintained when the nonessential intervening sequences located between 300 bp 5' and 8,500 bp 5' to the transcription initiation start site are eliminated (Fig 1C). The truncation of nonessential sequences is accomplished by standard molecular biological methodology well known in the art and results in a molecular chimera that can be used to direct liver-specific expression of VZV TK.

Similar to the regulatory structure of the ALB gene, the regulatory elements of the AFP genes promote tissue-specific expression of in certain liver pathologies, such as HCC (Mol.Cel.Biol. 6 : 477-487 (1986); Science 235: 53-58 (1987)). The regulatory elements of a mammalian AFP gene consist of a specific 5' promoter-proximal region (located in some mammalian species between 85 and 52 bp 5' to the gene). This sequence is essential for transcription in hepatomas. In addition, there are upstream (5') regulatory elements well defined for the murine AFP gene which behave as classical enhancers (Mol.Cel.Biol. 6 : 477-487 (1986); Science 235: 53-58 (1987)). These upstream regulatory elements are designated elements I, II, and III and are located between 1,000 to 7,800 bp 5' to the transcription initiation site for the AFP murine gene. These three enhancer domains are not functionally equivalent at generating tissue-specific expression of AFP. Elements I and II have the greatest capacity to direct liver-specific expression of AFP. It is important to note that the regulatory sequences of the alpha-fetoprotein gene advantageously contain the

sequences not only for tissue-specific transcriptional activation but also for repression of expression in tissues which should not express AFP. In a similar fashion the regulatory regions of the human alpha-fetoprotein gene have been characterised (J.B.C. 262 4812 (1987)). A structural gene placed in the correct orientation 3' to the AFP regulatory sequences will enable that structural gene to be selectively expressed in fetal liver, hepatomas, non seminomatous carcinomas of the testis, certain teratocarcinomas, certain gastrointestinal tumours and other normal and pathological tissues which specifically express AFP.

The present invention provides a molecular chimaera comprising a DNA sequence containing the coding sequence of the gene coding for a heterologous enzyme under the control of a transcriptional regulatory sequence in an expression cassette; the promoter capable of functioning selectively in a target cancer cell; for example one which is capable of transforming a cancer cell to selectively express thymidine kinase.

The present invention further provides in a preferred embodiment, a molecular chimaera comprising a transcriptional regulatory sequence, in particular a promoter which is selectively and activated in mammalian target tissues and operatively linked to the coding sequence for the gene encoding varicella zoster virus thymidine kinase (VZV TK).

In particular, the present invention provides a molecular chimaera comprising a DNA sequence of the coding sequence of the gene coding for the enzyme, which is preferably VZV TK, including an appropriate polyadenylation sequence, linked in a 3' position and in the proper orientation to a mammalian target tissue specific transcriptional regulatory sequence. Most preferably the expression cassette also contains an enhancer sequence.

The promoter and enhancer sequences, preferably, are selected from the transcriptional regulatory sequence for one of albumin (ALB), alpha-fetoprotein (AFP), carcino-embryonic antigen (CEA), tryrosine hydroxylase, choline acetyl transferase, neuron-specific enolase, glial fibro acid protein, insulin or gamma-glutamyltranspeptidase, dopadecarboxylase, HER2/neu or N-myc oncogene or other suitable genes. Most preferably the regulatory sequence for ALB or AFP are used to direct liver specific or hepatoma specific expression respectively.

The molecular chimaera of the present invention may be made utilising standard recombinant DNA techniques. Thus the coding sequence and polyadenylation signal of, for example, the VZV thymidine kinase (TK) gene (see Figs. 2A and 2B) is placed in the proper 3' orientation to the essential, ALB or AFP transcriptional regulatory elements. These molecular chimaeras enable the selective expression of VZV TK in cells which normally express ALB or AFP, respectively (Figure 3A and 3B). Expression of the VZV TK gene in mammalian liver, hepatomas, certain tumours of the gastrointestinal tract, nonseminomatous carcinomas of the testis, certain teratocarcinomas and other tumours will enable relatively nontoxic arabinosides and pyrimidines as herein defined to be selectively metabolised to cytotoxic and/or cytostatic metabolites.

Accordingly, in a second aspect, there is provided a method of constructing a molecular chimaera comprising linking a DNA sequence encoding a heterologous enzyme gene, eg. VZV TK to a tissue specific promoter.

In particular the present invention provides a method of constructing a molecular chimaera as herein defined, the method comprising ligating a DNA sequence encoding the coding sequence and polyadenylation signal of the gene for a heterologous enzyme, eg. VZV thymidine kinase to a mammalian tissue specific transcriptional regulatory sequence (eg. promoter sequence and enhancer sequence).

The VZV thymidine kinase coding sequence and 3' polyadenylation signal reside in an approximately 1,381 bp AccI/Nde I restriction endonuclease fragment (see Figure 2).

Preferably it is the 1381bp AccI/Nde I fragment containing the VZV TK coding sequence and polyadenylation signal that is ligated to the mammalian tissue specific promoter and enhancer sequences, although it will be appreciated that other DNA fragments containing the VZV TK gene could be used. Moreover, the VZV TK polyadenylation signal could be replaced with another suitable polyadenylation signal such as from the SV40 virus or other mammalian genes.

Preferably the promoter and enhancer sequences are selected from the transcriptional regulatory sequences for one of albumin (ALB), alpha-fetoprotein (AFP), carcino-embryonic antigen (CEA), tryrosine hydroxylase, choline acetyl transferase, neuron-specific enolase, glial fibro acidic protein, insulin, gamma glutamyltranspeptidase, dopa decarboxylase, HER2/neu or N-myc oncogenes or other suitable genes.

These molecular chimaeras can be delivered to the target cell by a delivery system. For administration to a patient, it is necessary to provide an efficient *in vivo* delivery system which stably integrates the molecular chimaera into the cells. known methods utilise techniques of calcium phosphate transfection, electroporation, microinjection, liposomal transfer, ballistic barrage or retroviral infection. For a review of this subject see Biotechnology Vol.6. No.7. 1988.

The technique of retroviral infection of cells to integrate artificial genes employs retroviral shuttle vectors which are known in the art, (see for example Mol. and Cell Biol Aug 86 p2895). Essentially, retroviral shuttle vectors are generated using the DNA form of the retrovirus contained in a plasmid. These plasmids also contain sequences necessary for selection and growth in bacteria. Retroviral shuttle vectors are constructed using standard molecular biology techniques well known in the art. Retroviral shuttle vectors have the parental endogenous retroviral genes (eg. *gag*, *pol*, and *env*) removed and the DNA sequence of interest inserted, such as the molecular chimaeras which have been described. They however, contain appropriate retroviral regulatory sequences for viral encapsidation, proviral insertion into the target genome, message splicing, termination and polyadenylation. Retroviral shuttle vectors have been derived from the Moloney murine leukemia virus (Mo-MLV) but it will be appreciated that other retroviruses can be used such as the closely related Moloney murine sarcoma virus. Certain DNA viruses may also prove to be useful as a delivery system. The bovine papilloma virus [BPV] replicates extrachromosomally so that delivery system based on BPV have the advantage that the delivered gene is maintained in a nonintegrated manner.

Thus according to a third aspect of the present invention there is provided a retroviral shuttle vectors containing the molecular chimaeras as hereinbefore defined.

The advantages of a retroviral-mediated gene transfer system are the high efficiency of the gene delivery to the targeted tissue, sequence specific integration regarding the viral genome (at the 5' and 3' long terminal repeat (LTR) sequences) and little rearrangements of delivered DNA compared to other DNA delivery systems.

Accordingly in a preferred embodiment of the present invention there is provided a retroviral shuttle vector comprising a DNA sequence comprising a 5' viral LTR sequence, a cis acting psi encapsidation sequence, a molecular chimaera as hereinbefore defined and a 3' viral LTR sequence (figure 4A and figure 4B).

In a preferred embodiment, and to help eliminate non-tissue-specific expression of the molecular chimaera, the molecular chimaera is placed in opposite transcriptional orientation to the 5' retroviral LTR (figure 4A and figure 4B). In addition, a dominant selectable marker gene may also be included which is transcriptionally driven from the 5' LTR sequence. Such a dominant selectable marker gene may be the bacterial neomycin-resistance gene NEO (Aminoglycoside 3' phosphotransferase type II), which confers on eukaryotic cells resistance to the neomycin analogue G418 sulphate (geneticin) (trade mark), (Figure 4A and 4B). The NEO gene aids in the selection of packaging cells which contain these sequences (see below).

The retroviral vector used in the examples is based on the Moloney murine leukemia virus but it will be appreciated that other vectors may be used. Such vectors containing a NEO gene as a selectable marker have been described, for example, the N2 vector (Science 230 : 1395-1398 (1985)).

A theoretical problem associated with retroviral shuttle vectors is the potential of retroviral long terminal repeat (LTR) regulatory sequences transcriptionally activating a cellular oncogene at the site of integration in the host genome. This problem may be diminished by creating SIN vectors (figure 4A). SIN vectors are self-inactivating vectors which contain a deletion comprising the promoter and enhancer regions in the retroviral LTR. The LTR sequences of SIN vectors do not transcriptionally activate 5' or 3' genomic sequences. The transcriptional inactivation of the viral LTR sequences diminishes insertional activation of adjacent target cell DNA sequences and also aids in the selected expression of the delivered molecular chimaera. SIN vectors are created by removal of approximately 299 bp in the 3' viral LTR sequence (Biotechniques 4 504-512 (1986)).

Thus preferably the retroviral shuttle vector of the present invention are SIN vectors.

Since the parental retroviral *gag*, *pol* and *env* genes have been removed from these shuttle vectors, a helper virus system may be utilised to provide the *gag*, *pol* and *env* retroviral gene products trans to package or encapsidate the retroviral vector into an infective virion. This is accomplished by utilising specialised "packaging" cell lines, which are capable of generating infectious, synthetic virus yet are deficient in the ability to produce any detectable wild-type virus. In this way the artificial synthetic virus contains a chimaera of the present invention packaged into synthetic artificial infectious virions free of wild-type helper virus. This is based on the fact that the helper virus that is stably integrated into the packaging cell contains the viral structural genes, but is lacking the *psi* site, a cis acting regulatory sequence which must be contained in the viral genomic RNA molecule for it to be encapsidated into an infectious viral particle.

Accordingly in a fourth aspect of the present invention there is provided an infective virion comprising a retroviral shuttle vector as hereinbefore described, said vector being encapsidated within viral proteins to create an artificial infective, replication-defective retrovirus.

Preferably the retroviral shuttle vector comprises a shuttle vector comprising a molecular chimaera

having the transcriptional regulatory sequence of AFP or ALB. In particular, the shuttle vector contains a AFP/VZV TK chimaera or ALB/VZV TK chimaera.

In addition to removal of the psi site, additional alterations can be made to the helper virus LTR regulatory sequences to ensure that the helper virus is not packaged in virions and is blocked at the level of reverse transcription and viral integration.

Alternatively, helper virus structural genes (i.e. gag, pol and env) may be individually and independently transferred into the packaging cell line. Since these viral structural genes are separated within the packaging cell's genome, there is little chance of covert recombinations generating wild-type virus.

In a fifth aspect of the present invention there is provided a method for producing infective virions of the present invention by delivering the artificial retroviral shuttle vector comprising a molecular chimaera of the invention, as hereinbefore described into a packaging cell line.

The packaging cell line may have stably integrated within it a helper virus lacking a psi site and other regulatory sequence as hereinbefore described, or alternatively the packaging cell line may be engineered so as to contain helper virus structural genes within its genome.

The present invention further provides an infective virion as hereinbefore described for use in therapy, particularly for use in the treatment of cancer and more particularly for use in the treatment of HCC, nonseminomatous carcinoma of the testis, certain teratocarcinomas and certain gastrointestinal tumours.

Selective expression of the heterologous enzyme, in particular thymidine kinase gene is accomplished by utilising tissue-specific, transcriptional regulatory (eg. enhancer and promoter) sequences. Selectivity may be additionally improved by selective infection of liver cells. The retroviral env gene present in the packaging cell line defines the specificity for host infection. The env gene used in constructing the packaging cell line is modified to generate artificial, infective virions that selectively infect hepatocytes. As an example a retroviral env gene introduced into the packaging cell may be modified in such a way that the artificial, infective virion's envelope glycoprotein selectively infect hepatocytes via the specific receptor mediated binding utilised by the hepatitis B virus (HBV).

HBV primarily infects hepatocytes via specific receptor mediated binding. The HBV proteins encoded by the pre-S1 and pre-S2 sequences play a major role in the attachment of HBV to hepatocytes (Hepadna Viruses edited Robinson et al 189-203, 205-221, 1987). The env gene of the packaging cell is modified to include the hepatocyte binding site of the large S HBV envelope protein. Such modifications of the env gene introduced into the packaging cell may be performed by standard molecular biology techniques well known in the art and will facilitate viral uptake in the target tissue.


The infective virion according to the invention may be formulated by techniques well known in the art and may be presented as a formulation with a pharmaceutically acceptable carrier therefor. Pharmaceutical acceptable carriers, in this instance, may comprise a liquid medium suitable for use as vehicles to introduce the infective virion into the patient. An example of such a carrier is saline. The infective virion may be a solution or suspension in such a vehicle. Stabilisers and antioxidants and/or other excipients may also be present in such pharmaceutical formulations which may be administered to a mammal by any conventional method eg oral or parenteral routes. In particular, the infective virion may be administered by intra-venous or intra-arterial infusion. In the case of treating HCC intra-hepatic arterial infusion may be advantageous.

Accordingly the invention provides a pharmaceutical formulation comprising an infective virion in admixture with a pharmaceutically acceptable carrier.

Additionally, the present invention provides methods of making pharmaceutical formulations as herein described comprising mixing an artificial infective virion, containing a molecular chimaera, with a pharmaceutically acceptable carrier.

Whilst any suitable compound which can be selectively converted by the enzyme may be utilised, the present invention further provides the use of compounds of formula I or II in the manufacture of a medicament for use in treating cancers capable of expressing VZV thymidine kinase. In particular for use in treating hepatocellular carcinoma (HCC).

6-Substituted purine arabinosides of formula (I) its salts and physiologically functional equivalents thereof as shown hereinbelow:




(I)

wherein

R_1 is halo, C_1-5 alkoxy, halogen-substituted C_1-5 alkoxy; an amino group which is mono- or di- substituted by C_1-5 alkyl, C_1-5 alkyl substituted by one or more fluorine atoms, C_3-6 cycloalkyl, or a nitrogen containing heterocycle containing C_4-7 carbon atoms and optionally a double bond; and R_2 is hydrogen, halo or amino are known as anti VZV and cytomegalovirus agents and their use and synthesis are described in European patent application published under No. 0294114.

Compounds of formula II are as shown hereinbelow



II

wherein X represents a vinylene or ethynylene group; R^1 represents an oxo or imino group; R^2 represents a hydrogen atom, C_1-2 alkyl, C_3-4 branched or cycloalkyl group e.g. isopropyl or cyclopropyl; R^3 represents a hydrogen atom or an acyl e.g. C_1-4 alkanoyl or benzoyl group optionally substituted for example by one or more halogen, alkyl, hydroxy or alkoxy substituents; and R^4 represents a hydrogen atom or a hydroxy group; providing that (a) when R^2 , R^3 and R^4 each represents a hydrogen atom, R^1 does not represent an oxo group.

It will be appreciated that when R^3 is not an acyl group, the compound of formula (I) or (II) may exist in its tautomeric form. Particularly preferred compounds of formula I and II are 9- β -Arabinofuranosyl-8-methoxy-9H-purine and 1-(β -D-arabinofuranosyl)-5-propynyluracil.

These compounds, and methods of their synthesis have been disclosed in European Patent application published under No. 0272065 as having anti VZV activity.

The above-mentioned pyrimidine nucleosides and purine arabinosides also include the pharmaceutically acceptable derivatives of such compounds, i.e. any pharmaceutically acceptable salt, ester, or salt of such ester, or any other compound which, upon administration to a human subject, is capable of providing (directly or indirectly) the active metabolite or residue thereof. Preferably the compound is orally active.

- 5 The amounts and precise regime in treating a mammal, will of course be the responsibility of the attendant physician, and will depend on a number of factors including the type and severity of the condition to be treated. However, for HCC, an intrahepatic arterial infusion of the artificial infective virion at a titre of between 2×10^5 and 2×10^7 colony forming units per ml (CFU/ml) infective virions is likely to be suitable for a typical tumour. Total amount of virions infused will be dependent on tumour size and would probably
- 10 be given in divided doses.

Drug treatment - Subsequent to infection with the infective virion, compounds according to the invention are administered which specifically require VZV TK activity for the critical first phosphorylation step in anabolism to cytotoxic or cytostatic metabolites.

- The dose of drug will advantageously be in the range 0.1 to 250 mg per kilogram body weight of recipient per day, preferably 0.1 to 100mg per kilogram bodyweight.

The following examples serve to illustrate the present invention but should not be construed as a limitation thereof:

20 Example 1

Construction of transcriptional regulatory sequence of albumin / VZV thymidine kinase molecular chimera

- 25 An approximately 1381 bp Acc I / Nde I DNA fragment (all restriction enzymes obtained from either Bethesda Research Laboratories, Gaithersburg MD, USA; New England Biolabs, Mass, USA; or Promega, Madison, WI, USA; all enzymatic reactions performed as specified by the supplier) containing the coding sequence and polyadenylation signal of the VZV TK gene was purified by electroelution using an elutrap electrophoresis chamber (by Schleicher and Schuell, Keene NH, USA) from a restriction endonuclease
- 30 digestion of an approximately 4886 bp plasmid, designated 22TK, containing an approximately 2200 bp EcoRI/BamHI fragment of the VZV TK genome (Virology 149 : 1-9 1986; supplied by J.Ostrove, NIH, Bethesda, Md.). The purified DNA fragment contains the entire VZV TK coding sequence and polyadenylation signal, but does not include any VZV TK promotional elements (see Fig. 2A and 2B). The 5' overhanging ends of the purified 1381 bp AccI/Nde I VZV TK fragment were made blunt by treatment with
- 35 the Klenow fragment of E.coli DNA polymerase I (Bethesda Research Laboratories, Gaithersburg, MD, USA) and deoxynucleotide triphosphate (dNTPS).

- An approximately 5249 bp plasmid, designated 2335A-1, containing approximately 2300 bp of a ALE E/P sequence was obtained from Richard Palmiter (University of Washington, Seattle, Washington, USA). This construct contains sequences necessary for liver-specific expression but lacks nonessential intervening
- 40 sequences. A unique BamH I restriction endonuclease recognition site is present at +23 relative to the start of transcription. 2335A-1 was digested with the restriction endonuclease BamH I and the 5' overhanging ends were made blunt by treatment with Klenow and dNTPs as described above.

- The ALE E/P VZV TK chimera was constructed by ligating the blunt ended AccI-NdeI fragment containing the VZV TK coding and polyadenylation sequences into the blunt ended BamH I site of 2335A-1
- 45 creating pCR73 using T4 DNA ligase (Bethesda Research Laboratories, Gaithersburg, MD) (Figure 5). Similar to all ligations described, the orientation of the ligated fragments was determined by restriction endonuclease digestions by methods well known in the art. Similar to all plasmids described in all examples, pCR73 contains essential sequences required for replication in bacteria and suitable for amplification by methods well known in the art. The ALB E/P VZV TK chimera was purified by
- 50 electroelution from pCR73 as an approximately 3880 bp SstI/KpnI restriction endonuclease fragment (Figure 5). The 3' overhanging ends were made blunt by treatment with T4 DNA polymerase and dNTPS. This SstI/KpnI blunt ended restriction fragment was subsequently introduced into a Moloney murine leukemia virus retroviral shuttle vector system (see below, example 3).

pCR73 was deposited at the ATTC on 18th August 1989 under Accession No. ATTC68077.

55

Example 2

Construction of transcriptional regulatory sequence of alphafetoprotein/VZV thymidine kinase

The VZV thymidine kinase coding sequence and polyadenylation site was isolated as an approximately 3,300 bp BamHI-XmnI restriction endonuclease fragment of pCR73 (figure 6). The 5' overhanging end of the BamHI restriction endonuclease site was made blunt by treatment with Klenow and dNTPs. This DNA fragment contains the complete coding sequence and the polyadenylation site of the VZV TK gene but does not contain any enhancer or promoter sequences. An approximately 9996 bp plasmid, pAF5.1-CAT, containing an approximately 5,100 bp of human 5' flanking DNA was obtained from T. Tamaoki, Univ. of Calgary, Canada. A DNA fragment spanning from approximately -5.1 kb to +29 of the human AFP gene was isolated from PAF5.1-CAT by digestion with XmnI and partial digestion with HindIII. This XmnI/HindIII fragment was ligated to the BamHI/XmnI VZV TK fragment using T4 DNA ligase to form pCR 77 (figure 6). The AFP E/P VZV TK chimera was purified by electroelution from PCR 77 as an approximately 8699 bp Aat II /PstI restriction endonuclease fragment. This fragment was then treated with T4 DNA polymerase and dNTPS as example 1 to produce a blunt end restriction fragment.

pCR77 was deposited at the ATCC on 18th August 1989, under Accession No. ATCC68079.

Example 3Construction of a retroviral shuttle vector construct containing the molecular chimera of example 1.

The retroviral shuttle vector, pCR74, containing the ALB E/P VZV TK chimera was constructed by ligating the purified SstI/KpnI blunt ended fragment of pCR73 into a Moloney murine leukemia retroviral vector designated N2(XM5) (Science 230 : 1395-1398, 1985) obtained from S. Karrison, NIH, Bethesda, MD, USA. N2(XM5) was digested with the restriction endonuclease XhoI and the 5' overhanging ends were made blunt by treatment with both Klenow and dNTPs prior to the ligation to the pCR73 SstI/KpnI fragment using T4 DNA ligase (Figure 5).

The retroviral shuttle vector pCR74 containing the ALB E/P VZV TK chimera has been characterised by restriction endonuclease mapping and DNA sequencing to confirm the primary sequence. The sequence flanking the junction of the ALB E/P to the VZV TK sequences is shown in Figure 7.

pCR74 was deposited at the ATCC on 18th August 1989 under Accession No. ATCC68078.

Example 4Construction of a retroviral shuttle vector construct containing the molecular chimera of example 2.

The retroviral shuttle vector pCR78 (figure 6) was constructed by ligating a purified AatII/PstI fragment of pCR77 containing the AFP E/P VZV TK chimera into N2(XM5) which was digested with XhoI and made blunt ended with T4 DNA polymerase and dNTPS as described in Example 3. The retroviral shuttle vector pCR78 containing the AFP E/P VZV TK chimera has been characterised by restriction endonuclease mapping and DNA sequencing to confirm the primary sequence. The sequence flanking the junction of AFP E/P to the VZV TK sequence is shown in figure 8.

pCR78 was deposited at the ATCC on 18th August 1989 under Accession No. ATCC68080.

Example 5Virus Production

The packaging cell line called PA317 obtained from ATCC, (ATCC CRL 9078), which has been previously described, has three alterations contained within the 5' LTR, psi regulatory sequence and 3' LTR (Mol. and Cell Biol 6 No.8 2895-2902 [1986]). The artificial retroviral constructs described in example 3 and 4 are placed into the packaging cell line by electroporation or infection. For electroporation, 20ug of linearized plasmid DNA is electroporated into 2 million PA317 cells in phosphate buffered sucrose using

280 volts, 25 microfarads of capacitance in a total volume of 0.8mls. One can obtain at least 150 G418 resistant colonies / 20ug plasmid DNA/2 million PA317 cells. For infection, 20ug of linearized plasmid DNA is electroporated into 2 million ecotropic packaging cells, such as Psi 2 cells. Two days later, the culture supernatant is used to infect the amphotropic packaging cell line PA317 and 418 resistant colonies isolated.

5 For both electroporation and infection techniques, G418 resistant colonies are single cell cloned by the limiting dilution method and analysed by Southern blots and titered in NIH 3T3 cells (ATCC) to identify the highest producer of full length virus. For PA317 cells containing pCR74, 17 single cell clones were isolated and DNA was extracted from 10 of these clones. Extensive Southern blot analysis using different restriction endonuclease enzymes and NEO and VZV TK sequences as radioactive hybridization probes was performed on these 10 DNA samples. Out of the 10 clones analysed, two showed no evidence of truncation and are considered full length. For PA317 cells containing pCR78, 29 single cell clones were isolated and DNA was obtained from 25 clones. Extensive Southern blot analysis using different restriction endonuclease enzymes and AFP, NEO and VZV TK sequences as radioactive hybridisation probes was performed on these 25 samples. Out of the 25 clones analysed, 5 showed no evidence of truncation and are considered

15 full length. Each packaging cell line containing a full length viral sequence was titered in NIH 3T3 cells which were thymidine kinase minus/minus using standard techniques.

Example 6

20 Infection of a human hepatoma cell line (positive control) with full length infective virions of Example 5 containing ALB/VZV TK or AFP/VZV TK with subsequent measurements of VZV Tx activity ara ATP production and drug sensitivity.

The replication-defective, full length, artificial retroviruses containing the ALB/VZV TK chimera or AFP/VZV TK chimera were used to infect a human hepatoma cell line called Hep G2 (ATCC KS 8065). Following infection and selection on 1mg geneticin/ml (Trade mark), the cells were assayed for VZV TK activity. In addition, the cells were incubated in the presence of (³H) labeled 9-(B-D-arabinofuranosyl)-6-methoxy-9H purine (designated as ara-M in the following tables and figures) with subsequent measurement of ara ATP. Finally, cells were cultured in the presence of the above mentioned compound and the IC₅₀ - (growth inhibition) was determined. Cells infected with no virus or N2 virus act as control samples for these experiments. N2 virus contain no VZV TK genetic material.

Table 1 demonstrates that the human hepatoma cells infected with either pCR74 or pCR78 containing viruses have 904 X or 52 X more VZV TX activity, respectively, compared to control cells.

9-(B-D-arabinofuranosyl)-6-methoxy-9H purine (designated as ara-m) can be selectively monophosphorylated by VZV TK with subsequent anabolism to cytotoxic ara ATP. Figure 9 demonstrates that Hep G2 cells which were infected with either pCR74 or pCR78 containing viruses and incubated in the presence of (³H) labelled 9-B-D arabinofuranosyl)-6-methoxy-9H purine had significant amounts of cytotoxic

40 (³H) araATP formation.

Hep G2 cells infected with the replication-defective, full length, artificial retroviruses containing the ALB/VZV TK chimera (pCR74) or AFP/VZV TK (PCR78) chimera were incubated in the presence of varying amounts of 9-(B-D-arabinofuranosyl)-6-methoxy-9H purine for 5 days and growth inhibition determined as measured by cell number and DNA content.

45 Table 2 demonstrates that the IC₅₀ (50% growth inhibition) of 9-(B-D-arabinofuranosyl)-6-methoxy-9H purine is greater than 2000μ M in control and N2 infected Hep G2 cells. Hep G2 cells infected with the replication-defective, full length, artificial retroviruses containing the ALB/VZV TX chimera (pCR74) or AFP/VZV TK (pCR78) chimeras, the IC₅₀ were 5μ M and 175μ M, respectively. Single cell cloning of Hep G2 cells containing the AFP/VZV TK (pCR78) chimera indicated that the IC₅₀ levels of 9-(B-D-arabinofuranosyl)-6-methoxy-9H purine can be further decreased to approximately 40μ M.

50

Example 7

56

Selectivity of Expression of VZV TK.

Five human, non-hepatoma cell lines were infected with replication-defective, full length, artificial

retroviruses containing the ALB/VZV TK chimaera (pCR74). These cell lines were WIDR (ATCC CCL218), IMR90 (ATCC CCL186), MCF7 (ATCC HTB22), Detroit 555 (ATCC CCL110) and SW480 (ATCC CCL228). Subsequent to infection and selection on geneticin (Trade mark), these cells were assayed for VZV TK activity and growth inhibition in the presence of 9-(B-D-arabinofuranosyl)-6-methoxy-9H purine, as described above. There was no increase in VZV TK activity or drug sensitivity to 9-(B-D-arabinofuranosyl)-6-methoxy-9H purine in these five non-hepatoma cell lines infected with replication-defective, full length, artificial retroviruses containing the ALB/VZV TK chimaera (pCR74) compared to parental cell lines which were not infected. This demonstrates the selectivity of expression for VZV TK in hepatoma verse non-hepatoma cells.

LEGEND TO FIGURES

Figure 1 : Schematic representation of albumin enhancer and promoter sequences in relation to the albumin gene (IA), a heterologous gene (IB) and heterologous gene without non-essential sequences.

Figure 2 : Diagram of Varicella Zoster Thymidine Kinase Gene.

Figure 2B : VZV TK gene - 1st sequence.

Figure 3A : Albumin transcriptional regulatory sequence / VZV TK molecular chimaera.

Figure 3B : Alpha-fetoprotein transcriptional regulatory sequence / VZV TK molecular chimaera.

Figure 4 : Proviral form of retrovirus containing alpha-fetoprotein / VZV TK molecular chimaera.

Figure 4B : pCR78.

Figure 5 : Flow chart showing the construction of pCR74.

Figure 6 : Flow chart showing the construction of pCR78.

Figure 7 : Sequence flanking ALE E/P to VZV TK in pCR74.

Figure 8 : Sequence flanking AFP E/P to VZV TK in pCR78.

Figure 9 : Production of ara ATP with cells infected with controls, pCR74, pCR78.

Table 1

| VZV TK activity in Hep G2 cells infected with replication-defective, full length, artificial retroviruses containing ALB/VZV TK chimaera (pCR74) or AFP/VZV TK chimaera (pCR78). VZV Tk activity was quantitated as amount of ara M phosphorylate per mg cellular protein per 30 minutes. | | |
|---|--|----------|
| Virus | VZV TK Enzymatic Activity nMoles ara MP/ μ g protein/30 mins | Increase |
| None | 9 | 0x |
| N2 | 4 | 0x |
| pCR74 | 4521 | 904x |
| pCR78 | 258 | 52x |

Table 2


| Growth inhibition in Hep G2 cells infected with replication-defective, full length, artificial retroviruses containing ALB/VZV TK chimaera (pCR74) or AFP/VZV TK chimaera (pCR78). | |
|--|--|
| Virus | IC50 for 9-(B-D-arabinofuranosyl)-6-methoxy-9H-purine |
| None | >2000 μ M |
| N2 | >2000 μ M |
| pCR74 | 5 μ M |
| pCR78 | 175 μ M |

Claims

1. A molecular chimaera comprising a transcriptional regulatory sequence capable of being selectively activated in a mammalian target tissue, a DNA sequence operatively linked to the transcriptional regulatory sequence and encoding a heterologous enzyme, the enzyme capable of catalysing the production of an agent toxic to the target tissue.
2. A chimaera as claimed in claim 1 wherein the transcriptional regulatory sequence comprises a promoter.
3. A chimaera as claimed in claims 1 or 2 additionally comprising a polyadenylation signal downstream of the DNA sequence encoding the heterologous enzyme.
4. A chimaera as claimed in claims 1, 2 or 3 wherein the transcriptional regulatory sequence additionally comprises an enhancer sequence.
5. A chimaera as claimed in any one of claims 2 to 4 wherein the promoter is selected from the profloters of albumin, alphafetoprotein, carcino-embryonic antigen, tyrosine hydroxylase, choline acetyl transferase, neuron specific enolase, glial fibro acid protein, insulin, gamaglutamyltranspeptidase, dopa decarboxylase, HER2/neu and N-myc oncogenes.
6. A chimaera as claimed in claim 4 wherein the enhancer is selected from the enhancers of albumin, alphafetoprotein, carcino-embryonic antigen, tyrosine hydroxylase, choline acetyl transferase, glial fibro acid protein, insulin, gama glutamyl transpeptidase, dopa decarboxylase, HER2/neu and N-myc oncogenes.
7. A molecular chimaera as claimed in any one of claims 1 to 6 wherein the enzyme is selected from varicella zoster virus thymidine kinase, carboxypeptidase G2, alkaline phosphatase, penicillin-V amidase and non-mammalian cytosine deaminase.
8. A molecular chimaera as claimed in any one of claims 1 to 7 wherein the enzyme is varicella zoster virus thymidine kinase.
9. A molecular chimaera comprising a DNA sequence encoding the gene for varicella zoster virus thymidine kinase operatively linked to the transcriptional regulatory sequence for albumin.
10. A molecular chimaera comprising a DNA sequence encoding varicella zoster virus thymidine kinase operatively linked to the transcriptional regulatory sequence for alphafetoprotein.
11. A retroviral shuttle vector containing a molecular chimaera as claimed in any one of claims 1 to 10.
12. A vector as claimed in claim 11 comprising a 5' viral long terminal repeat (LTR) sequence, a cis-acting psi encapsidation sequence, the molecular chimaera of any one of claims 1 to 10 and a 3' viral LTR sequence.
13. A vector as claimed in claim 12 wherein the molecular chimaera is oriented in the opposite direction to the 5' retroviral LTR.
14. A vector as claimed in claim 12 or 13 additionally comprising a DNA sequence encoding a dominant

selectable marker operatively linked to the 5' LTR sequence.

15. A vector as claimed in claim 14 wherein the selectable marker sequence is a NEO gene.
16. A vector as claimed in any one of claims 11 to 15 being a self inactivating (SIN) vector.
17. An infective virion encapsidating a vector as claimed in any of claims 11 to 16.
18. An infective virion as claimed in claim 17 engineered so as to selectively infect a target tissue.
19. An infective virion as claimed in any of claims 17 or 18 which is replication-defective.
20. An infective virion as claimed in any of claims 17 to 19 wherein the env gene of the virion is modified so as to facilitate cell specific viral uptake.
21. An infective virion as claimed in claim 20 wherein the env gene is modified to include the hepatocyte binding site of the large S HBV envelope protein.
22. A molecular chimera as claimed in any one of claims 1 to 10 for use in medical therapy.
23. A pharmaceutical formulation comprising an infective virion as claimed in any one of claims 17 to 21 with a pharmaceutically acceptable carrier therefore.
24. An infective virion as claimed in any one of claims 17 to 21 for use in medical therapy.
25. Use of an infective virion as claimed in any one of claims 17 to 21 in the manufacture of a medicament for use in the treatment of mammalian cancers.
26. Use of a compound in the manufacture of a medicament for use in treating a cancer capable of expressing a heterologous enzyme, said compound being selectively catalysed by the enzyme either directly or through an intermediate to a cytotoxic or cytostatic metabolite.
27. Use of a compound or a salt or physiologically functional derivative thereof in the manufacture of a medicament for use in treating a cancer capable of expressing VZV thymidine kinase wherein the compound is of formula I:




(I)

wherein

R₁ is halo, C₁₋₅ alkoxy, halogen-substituted C₁₋₅ alkoxy; an amino group which is mono- or di- substituted by C₁₋₅ alkyl, C₁₋₅ alkyl substituted by one or more fluorine atoms, C₃₋₆ cycloalkyl, or a nitrogen containing heterocycle containing C₄₋₇ carbon atoms and optionally a double bond; and R₂ is hydrogen, halo or amino;

or of formula II:



wherein X represents a vinylene or ethynylene group; R¹ represents an oxo or imino group; R² represents a hydrogen atom, C₁₋₂ alkyl, C₃₋₄ branched or cycloalkyl group e.g. isopropyl or cyclopropyl; R³ represents a hydrogen atom or an acyl e.g. C₁₋₄ alkanoyl or benzoyl group optionally substituted for example by one or more halogen, alkyl, hydroxy or alkoxy substituents; and R⁴ represents a hydrogen atom or a hydroxy group; providing that (a) when R², R³ and R⁴ each represents a hydrogen atom, R¹ does not represent an oxo group.

28. Use of an infective virion as claimed in claims 17 to 21 and a compound which can be selectively catalysed by a heterologous enzyme to cytostatic or cytotoxic metabolite for concomitant use in therapy.

29. Any one of pCR73, pCR74, pCR77 or pCR78.

Claims for the following Contracting States: ES, GR.

1. A process for the production of a molecular chimaera comprising linking a transcriptional regulatory sequence capable of being selectively activated in a mammalian target tissue, to a DNA sequence encoding a heterologous enzyme; the enzyme capable of catalysing the production of an agent toxic to the target tissue.
2. A process as claimed in claim 1 wherein the transcriptional regulatory sequence comprises a promoter.
3. A process as claimed in claim 1 or 2, wherein the DNA sequence encoding the enzyme additionally comprises a polyadenylation signal downstream from the enzyme.
4. A process as claimed in claim 1, 2 or 3 additionally comprising linking an enhancer sequence to the DNA sequence encoding the heterologous enzyme.
5. A process as claimed in any of claims 2 to 4 wherein the promoter is selected from the promoters of albumin, alphafeto-protein, carcino-embryonic antigen, tyrosine hydroxylase, choline acetyl transferase, neuron specific enolase, glial fibro acid protein, insulin, gamaglutamyltranspeptidase, dopa decarboxylase, HER2/neu and N-myc oncogenes.
6. A process as claimed in claim 4 wherein the enhancer is selected from the enhancers of albumin, alphafeto-protein, carcino-embryonic antigen, tyrosine hydroxylase, choline acetyl transferase, glial fibro acid protein, insulin, gama glutamyl transpeptidase, dopa decarboxylase, HER2/neu and N-myc oncogenes.
7. A process as claimed in any one of claims 1 to 6 wherein the enzyme is selected from varicella zoster virus thymidine kinase, carboxypeptidase G2, alkaline phosphatase, penicillin-V amidase and non-mammalian cytosine deaminase.
8. A process as claimed in any one of claims 1 to 7 wherein the enzyme is varicella zoster virus thymidine kinase.
9. A process for the production of a molecular chimaera comprising a DNA sequence encoding the gene for

varicella zoster virus thymidine kinase operatively linked to the transcriptional regulatory sequence for albumin, the process comprising linking the gene to the transcriptional regulatory sequence.

10. A process for the production of a molecular chimaera comprising a DNA sequence encoding varicella zoster virus thymidine kinase operatively linked to the transcriptional regulatory sequence for α -phafetoprotein, the process comprising linking the gene to the transcriptional regulatory sequence.
11. A process for the production of a retroviral shuttle vector containing a molecular chimaera as produced by the process of any one of claims 1 to 10 comprising ligating DNA sequences containing
 - a 5' viral LTR sequence
 - a cis acting psi encapsidation sequence,
 - the molecular chimaera produced by the process of any one of claims 1 to 10 and
 - a 3' viral LTR.
12. A process as claimed in claim 11 wherein the molecular chimaera is arranged in opposite transcriptional orientation to the 5' viral LTR sequence.
13. A process as claimed in claims 11 or 12 wherein a selectable marker gene is additionally incorporated in the retroviral shuttle vector.
14. A process as claimed in claim 13 wherein the selectable marker gene is the aminoglycoside 3-phosphotransferase Type II (NEO) gene.
15. A process for the production of an infective virion comprising encapsidating a retroviral shuttle vector produced in the manner of any one of claims 11-14 into the virion.
16. A process for the production of an infective virion comprising delivering a retroviral shuttle vector into a packaging cell line.
17. A process for the production of an infective virion capable of selective infection of a target tissue, comprising modifying the env protein of the virion to facilitate cell specific viral uptake.
18. A process for producing pharmaceutical formulation comprising mixing an infective virion produced in the manner of any of claims 11-15, with a pharmaceutically acceptable carrier.

Fig. 1A




Fig. 1B






Fig. 1C



┐ transcription initiation start site.

Fig. 2A

Diagram of the Varicella Zoster Thymidine Kinase Gene.

*Fig. 2B*

Sequence of the Varicella zoster thymidine kinase domain. Shown is the sequence of the VZV TK gene and the 5' and 3' flanking regions (bases 64276 to 66255 as reported in Gen. Virol. 67: 1759-1816, 1986). The VZV TATA box and polyadenylation are underlined. The *Acc* I and *Nde* I restriction endonuclease sites used to subclone the 1381 bp *Acc* I/*Nde* I fragment containing the VZV TK coding sequence and polyadenylation signal are shown. This 1381 bp fragment is ligated 3' and in the proper orientation to liver specific or hepatoma specific transcriptional regulatory sequences to achieve liver specific or hepatoma specific expression respectively.

Fig. 2B (cont. 1)

10 20 30 40 50 60
 CCTGTAACAGGTTTCAGACCCCGTTGAGATACAAACACAAGGAGGGGGTCCACCATTATTT
 70 80 90 100 110 120
 CATCAGATCCCGTGGGTGTGGTTTCTTTATTAAAGCCATGGTATCCCTCAGCTGGCGCA
 TATA Box
 130 140 150 160 170 180
 TACCCCTCGCAAAACTGGTGATACTTAGTAGGGGTATGTATATTAGCGCTAAACGGCAAG
 190 200 210 220 230 240
 ATTTTAATTCCACTATAAAACAAACGGTCTTTCCGGCACCCTGGATTCCGTTTGTATAA
 250 260 270 280 290 300
 TACAAACACAATCGGGGCGTGGCGTCCCAAATTTACTTCAAACGACATTGATATGCGTA
 310 320 330 340 350 360
 CAGCCCTTTGAACATCCACGTGGGATAACGGCGACAGGAGTTTTGCCAGCCTCGGGTTGA
 370 380 390 400 410 420
 ACGCGTCCGCGAAACCTCGACGTACGTTATCAATATCCTTTTTGAGTACATCGTAAAAAC
 430 440 450 460 470 480
 GAGTGTGGCAACGTTGTCCCAAACGAAAACACTTGGCCCGAATTGCGACTAGCGGACATAT
 490 500 510 520 530 540
 TTGAAGTTCGGTCCCAGAAGATAACCTAAGACGCGTTTGTCTACAATAAACATGTCAACG
 Acc I MetSerThr
 550 560 570 580 590 600
 GATAAAACCGATGTAAAAATGGGCGTTTTGCGTATTTATTTGGACGGGGCGTATGGAATT
 AspLysThrAspValLysMetGlyValLeuArgIleTyrLeuAspGlyAlaTyrGlyIle
 610 620 630 640 650 660
 GGAAAAACGACCCCGCCGGAAGAAATTTTACACCACTTTGCAATAACACCAAACCGGATC
 GlyLysThrThrAlaAlaGluGluPheLeuHisHisPheAlaIleThrProAsnArgIle
 670 680 690 700 710 720
 TTACTCATTTGGGGAGCCCTGTCTGATTGGCGTAACCTTGCAGGGGAGGACGCCATTTGC
 LeuLeuIleGlyGluProLeuSerTyrTrpArgAsnLeuAlaGlyGluAspAlaIleCys
 730 740 750 760 770 780
 GGAATTTACGGAACACAAACTCGCCGTCTTAATGGAGACGTTTCGCCTGAAGACGCACAA
 GlyIleTyrGlyThrGlnThrArgArgLeuAsnGlyAspValSerProGluAspAlaGln
 790 800 810 820 830 840
 CGCCTCAGGGCTCATTTTCAGAGCCTGTTCTGTCTCCGCATGCAATTATGCATGCGAAA
 ArgLeuThrAlaHisPheGlnSerLeuPheCysSerProHisAlaIleMetHisAlaLys
 850 860 870 880 890 900
 ATCTCGGCATTGATGGACACAAGTACATCGGATCTCGTACAAGTAAATAAGGAGCCGTAT
 IleSerAlaLeuMetAspThrSerThrSerAspLeuValGlnValAsnLysGluProTyr


Fig.2B(cont.2)

910 920 930 940 950 960
 AAAATTATGTTATCCGACCGACACCCAATCGCCTCAACTATATGTTTTGCCCTTGTCAGAG
 LysIleMetLeuSerAspArgHisProIleAlaSerThrIleCysPheProLeuSerArg
 970 980 990 1000 1010 1020
 TACTTAGTGGGAGATATGTCCCCAGCGCGCTTCCTGGGTATTGTTTACGCTTCCCGCT
 TyrLeuValGlyAspMetSerProAlaAlaLeuProGlyLeuLeuPheThrLeuProAla
 1030 1040 1050 1060 1070 1080
 GAACCCCCGGGACCAACTTGGTAGTTTGTACCGTTTCACTCCCCAGTCATTATCCAGA
 GluProProGlyThrAsnLeuValValCysThrValSerLeuProSerHisLeuSerArg
 1090 1100 1110 1120 1130 1140
 GTAAGCAAACGGGCGGACCGGGAGAAACGGTTAATCTGCCGTTTGTATTGGTTCTGAGA
 ValSerLysArgAlaArgProGlyGluThrValAsnLeuProPheValMetValLeuArg
 1150 1160 1170 1180 1190 1200
 AATGTATATATAATGCTTATTATAACAATTATTTCTTAAACTAACAACTGGCAGCG
 AsnValTyrIleMetLeuIleAsnThrIleIlePheLeuLysThrAsnAsnTrpHisAla
 1210 1220 1230 1240 1250 1260
 GGCTGGAACACACTGTCTTTTGTAAATGATGATTTTAAACAGAAATTACAAAAATCCGAG
 GlyTrpAsnThrLeuSerPheCysAsnAspValPheLysGlnLysLeuGlnLysSerGlu
 1270 1280 1290 1300 1310 1320
 TGTATAAACTACGCGAAGTACCTGGGATTGAAGACACGTTATTCGCCGTGCTTAAACTT
 CysIleLysLeuArgGluValProGlyIleGluAspThrLeuPheAlaValLeuLysLeu
 1330 1340 1350 1360 1370 1380
 CCGGAGCTTTGCGGAGAGTTTGGAAATATTCTGCCGTTATGGGCATGGGGAATGGAGACC
 ProGluLeuCysGlyGluPheGlyAsnIleLeuProLeuTrpAlaTrpGlyMetGluThr
 1390 1400 1410 1420 1430 1440
 CTTTCAAACCTGCTTACGAAGCATGTCTCCGTTCTGTTATTCGTTAGAACAGACACCCAG
 LeuSerAsnCysLeuArgSerMetSerProPheValLeuSerLeuGluGlnThrProGln
 1450 1460 1470 1480 1490 1500
 CATGCGGCACAAGAACTAAAACTCTGCTACCCAGATGACCCCGGCAACATGTCTCTCC
 HisAlaAlaGlnGluLeuLysThrLeuLeuProGlnMetThrProAlaAsnMetSerSer
 1510 1520 1530 1540 1550 1560
 GGTGCATGGAATATATTGAAAGAGCTTGTAAATGCCGTTTCAGGACAACACTTCCTAAATA
 GlyAlaTrpAsnIleLeuLysGluLeuValAsnAlaValGlnAspAsnThrSerEnd
 1570 1580 1590 1600 1610 1620
 TACCTAGTATTTACGTATGTACCAGTAAAAAGATGATACACATTGTCTACTCGCGTGTA
 Polyadenylation Signal
 1630 1640 1650 1660 1670 1680
 CGTGTCTTTTCTTTTATATATGCGTCATTATTACCACATCCTTTAATCCCGCCTTTAT
 1690 1700 1710 1720 1730 1740
 CTCCCTAAACGGAGTGGTAATATTAAAGCCGCCAAGCCTGTTGGTGGGTGAGGAGGGG
 1750 1760 1770 1780 1790 1800
 TAAAGGCACGCTGTGTGCATAACGTTGCGGTGATATTGTAGCGCAAGTAACAGCGACTAT

Fig. 2B (cont. 3)


| | | | | | |
|--|------|------|------|------|------|
| 1810 | 1820 | 1830 | 1840 | 1850 | 1860 |
| GTTTGCCTAGTTTTAGCGGTGGTAATTCTTCCTCTGTGGACCACGGCTAATAAATCTTA | | | | | |
| 1870 | 1880 | 1890 | 1900 | 1910 | 1920 |
| CGTAACACCAACCCCTGCGACTCGCTCTATCGGACATATGTCTGCTCTTCTACGAGAATA | | | | | |
| Nde I | | | | | |
| 1930 | 1940 | 1950 | 1960 | 1970 | 1980 |
| TTCCGACCGTAATATGTCTCTGAAATTAGAAGCCTTTTATCCTACTGGTTTCGATGAAGA | | | | | |

Fig. 3A



Results in liver-specific expression of VZV TK.

Fig. 3B




Results in hepatoma-specific expression of VZV TK in addition to other neoplastic tissues which express AFP such as certain tumors of the gastrointestinal tract and testis.

* | * polyadenylation signal


└─┐ transcription initiation start site.


Fig. 4A


Proviral form of artificial retroviral shuttle vector containing the artificial molecular chimaera of AFP transcriptional regulatory sequences and the coding sequence of the VZV TK gene.





KEY → direction of transcription

 protein coding sequence

 transcription initiation start site

 polyadenylation signal for the VZV TK gene and in 3' LTR

 long terminal repeat regulatory sequence

 psi site, cis acting regulatory sequence


 the transcriptional regulatory sequences are deleted from the 3' LTR to create a SIN vector (self-inactivating vector), SIN vectors will produce a provirus incorporated into the target cell with both LTR transcriptional regulatory sequences deleted. This will produce a provirus with the AFP transcriptional regulatory sequences (or others as indicated) as the only functional promoter and enhancers in the provirus.

Fig. 4B

Proviral form of the artificial retroviral shuttle containing the artificial molecular chimaera of AFP transcriptional regulatory sequences and the coding sequence of the VZV TK gene. Illustrated is this artificial shuttle vector contained in a plasmid for amplification in bacteria. The illustrated plasmid is a derivative of PBR 322. The shuttle vector is a derivative of the Moloney murine leukemia virus. Such shuttle vectors based on the Moloney murine leukemia virus have been described as exemplified by the N2 vector (Science 230 : 1395 - 1398 [1985]).

ENZYMES #Sites

1 HIND3 5

JUNCTIONS:

2 PST1/XHO1 1

3 AAT2/XHO1 1

Tic=1600




Fig. 5. SUMMARY FLOW CHART FOR THE CONSTRUCTION OF pCR74 THAT IS DETAILED IN EXAMPLES 1 AND 3




Fig. 6. SUMMARY FLOW CHART FOR THE CONSTRUCTION OF pCR78 THAT IS DETAILED IN EXAMPLES 2 AND 4.




Fig. 6(cont.)




Fig. 7.

Sequences flanking the junction of the murine ALB E/P to the VZV TK sequence in pCR74. Sequences 1-140 are from the murine ALB E/P. Sequences 141-276 are from VZV. The ALB proximal promoter element is double underlined. The start of RNA transcription is marked by an asterisk (*). The BamH I site is underlined. The vertical line mark the junction between ALB and VZV sequences. The displayed VZV coding sequence is translated.

```

      10      20      30      40      50      60
ATGGTATGATTTTGTAAATGGGGTAGGAACCAATGAAATGCCAGGTAAGTATGGTTAATGA

      70      80      90      100     110 *    120
TCTACAGTTATTGGTTAAAGAAGTATATTAGAGCGAGTCTTTCTGCACACAGATCACCTT

      130     140|    150     160     170     180
TCCTATCAACCCCGGGATCCTACAATAAACATGTCAACGGATAAAACCGATGTAAAAATG
          BamHI |           MetSerThrAspLysThrAspValLysMet

      190     200     210     220     230     240
GGCGTTTTCGTATTTATTTGGACGGGGCGGTATGGAATTGGAAAAACGACCGCCGCCGAA
GlyValLeuArgIleTyrLeuAspGlyAlaTyrGlyIleGlyLysThrThrAlaAlaGlu

      250     260     270
GAATTTTACACCACTTTGCAATAACACCAAACCGG
GluPheLeuHisHisPheAlaIleThrProAsnArg

```

Fig. 8.

Sequences flanking the junction of the human AFP E/P to the VZV TK sequences in pCR78. Sequences 1-73 are from the human AFP E/P. Sequences 93-228 are from VZV. The sequences between the two vertical lines are linker sequences. The AFP proximal promoter element is double underlined. The start of RNA transcription is marked by an asterisk (*). The displayed VZV coding sequence is translated.

```

      10      20      30      40      *      50      60
GCATTGCCTGAAAAGAGTATAAAAGAATTTTCAGCATGATTTTCCATATTGTGCTTCCACC

      70      80      90      100      110      120
ACTGCCAATAACACCGGATCGCAAGCTGATCCTACAATAAACATGTCAACGGATAAAACC
                               MetSerThrAspLysThr

      130      140      150      160      170      180
GATGTAAAAATGGGCGTTTTCGCTATTTATTTGGACGGGGCGTATGGAATTGGAAAACG
AspValLysMetGlyValLeuArgIleTyrLeuAspGlyAlaTyrGlyIleGlyLysThr

      190      200      210      220
ACCGCCGCCGAAGAATTTTACACCACTTTGCAATAACACCAAACCGG
ThrAlaAlaGluGluPheLeuHisHisPheAlaIleThrProAsnArg

```


Fig. 9.

